

Inquadramento anatomo-patologico

Prof. Giovanni Lanza

Il percorso del paziente con neoplasia
neuroendocrina nella provincia di Ferrara

Società Medico Chirurgica

Cona – Ferrara, 12 ottobre 2019

Neoplasie neuroendocrine


Gruppo di tumori eterogeneo per numerose caratteristiche:

- Origine
- Modalità di sviluppo
- Stato funzionale
- Aspetto istologico
- Comportamento biologico e clinico


Neoplasie neuroendocrine

Ruolo del patologo


- Diagnosi
 - Tumore primitivo e metastasi
- Grading
- Staging (TNM)
- Valutare la presenza di altre alterazioni patologiche rilevanti
- Marcatori biomolecolari prognostici e predittivi




Tumore neuroendocrino (NET)




Tumore neuroendocrino (NET) - cromogranina




Tumore neuroendocrino (NET)



Tumore neuroendocrino (NET) - sinaptofisina



Tumore neuroendocrino (NET) dell'ileo



Tumore neuroendocrino (NET) dell'ileo - cromogranina




FIGURE 29.21 A poorly differentiated, small cell–type neuroendocrine carcinoma in the gallbladder.

Copyright © 2015, 2009, 2004 by Saunders, an imprint of Elsevier Inc.

Ulteriori informazioni patologiche - sede

- La determinazione della sede del tumore primitivo può essere di rilevanza clinica
- Esistono diversi marcatori anche se non completamente specifici
 - **TTF1**: neoplasie neuroendocrine polmonari
 - **CDX2**: neoplasie neuroendocrine intestinali




FIGURE 29.1 Incipient neuroendocrine tumor in the setting of autoimmune gastritis. Linear and micronodular (*arrow*) enterochromaffin-like (ECL) cell hyperplasia, highlighted by chromogranin immunohistochemical stain, is common in the setting of secondary hypergastrinemia caused by autoimmune gastritis. These lesions are regarded as precursors of type A gastric neuroendocrine tumors.




Figure 6 | A small neuroendocrine tumour (carcinoid) in the stomach of a patient with autoimmune atrophic gastritis. The tumour is circumscribed, and although it expands into the submucosa, the growth pattern is not infiltrative. **a** | Staining with hematoxylin and eosin. **b** | Staining with anti-chromogranin antibodies.




FIGURE 29.26 All high-grade (dedifferentiated) goblet cell carcinoids (i.e., adenocarcinoma ex-goblet cell carcinoid) reveal at least some foci of the conventional goblet cell carcinoid pattern, but they also may display high-grade features and mixed patterns, as shown in this example by marked cytologic atypia, irregularity of the glandlike structures, and few cordlike and individual cells.

Classificazione WHO 2010


Neoplasie neuroendocrine apparato digerente

	Grado	Mitosi (X 10 HPF)	Ki-67 index (%)
NET Tumore neuroendocrino	G1	< 2	<= 2
NET Tumore neuroendocrino	G2	2 - 20	3 - 20
NEC Carcinoma neuroendocrino a piccole o a grandi cellule	G3	> 20	> 20

NET

Grado 1


Grado 2



Grandi cellule

Piccole cellule

Grado 3 - NEC



PanNET G1

PanNET G2




Fig. 2 Ki-67 staining of NEN from different sites: **a** a grade 1 NET from the ileum, **b** a grade 2 NET from the lung (atypical carcinoid), **c** a grade 3 NET from the pancreas, and **d** a NEC (SCLC) from the lung

Classificazione WHO 2015

Tumori neuroendocrini del polmone

- **Carcinoide tipico**
 - < 2 mitosi per mm quadrato, assenza di necrosi, diametro $\geq 0,5$ cm* (sopravvivenza a 5 anni 90%)
- **Carcinoide atipico**
 - 2-10 mitosi per mm quadrato e/o necrosi (sopravvivenza a 5 anni 60%)
- **Carcinoma a piccole cellule**
- **Carcinoma neuroendocrino a grandi cellule**
- * Proliferazioni nodulari neuroendocrine < 0,5 cm sono classificate come tumourlet




Fig. 3. Well differentiated G3 neuroendocrine tumor maintains organoid and trabecular pattern (A) with a mitotic count 2-20/10 high power fields (B) and a Ki-67 labeling index > 20% (C).


2017 WHO classification and grading of pancreatic neuroendocrine neoplasms (PanNENs)

Classification/grade	Ki-67 index	Mitotic index
Well-differentiated PanNENs (PanNETs)		
PanNET G1	< 3%	< 2
PanNET G2	3-20%	2-20
PanNET G3	> 20%	> 20
Poorly differentiated PanNENs (PanNECs)		
PanNEC (G3) Small cell type Large cell type	> 20%	> 20
Mixed neuroendocrine-non-neuroendocrine neoplasms		

2019 WHO Classification and grading criteria for neuroendocrine neoplasms of the digestive system


Terminology/Differentiation/Grade	Ki-67 index	Mitotic rate (mitoses/2 mmq)
Neuroendocrine tumour (NET) Well differentiated		
NET G1 Low	< 3%	< 2
NET G2 Intermediate	3-20%	2-20
NET G3 High	> 20%	> 20
Neuroendocrine carcinoma (NEC) Poorly differentiated		
NEC, small cell type (SCNEC) High NEC, large cell type (LCNEC) High	> 20%	> 20
Mixed neuroendocrine-non-neuroendocrine neoplasm Well or poorly differentiated	Variable	Variable

Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts

Iván González,¹  Hsiang-Chih Lu,¹ Jared Sninsky,² Chen Yang,^{1,†} Kumar Bishnupuri,³ Brian Dieckgraefe,³ Dengfeng Cao¹  & Deyali Chatterjee¹

¹Department of Pathology and Immunology, ²Department of Medicine, and ³Division of Gastroenterology, Washington University School of Medicine, Saint Louis, MO, USA

Conclusions: The nuclear reactivity and the high sensitivity and specificity of INSM1 make it a preferred neuroendocrine marker. In conclusion, INSM1 can be used as a single first-line marker for primary and metastatic GEP-NEN.



**OPEN ACCESS**

ORIGINAL ARTICLE

Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system

Xiafei Hong,¹ Sitan Qiao,^{2,3} Fuqiang Li,^{2,3} Wenze Wang,⁴ Rui Jiang,¹ Huanwen Wu,⁴ Hao Chen,¹ Lulu Liu,⁵ Junya Peng,⁵ Jing Wang,⁴ Congwei Jia,⁴ Xiaolong Liang,⁴ Hongmei Dai,¹ Jialin Jiang,¹ Taiping Zhang,¹ Quan Liao,¹ Menghua Dai,¹ Lin Cong,¹ Xianlin Han,¹ Dan Guo,^{5,6} Zhiyong Liang,⁴ Dongjing Li,⁷ Zetian Zheng,^{2,3} Chen Ye,^{2,3} Siliang Li,^{2,3} Yupei Zhao,^{1,8} Kui Wu,^{2,3} Wenming Wu¹